Anzeige
Mehr »
Samstag, 07.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PTTB | ISIN: US12674W1099 | Ticker-Symbol:
NASDAQ
06.06.25 | 21:59
2,475 US-Dollar
+13,53 % +0,295
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
CABALETTA BIO INC Chart 1 Jahr
5-Tage-Chart
CABALETTA BIO INC 5-Tage-Chart

Aktuelle News zur CABALETTA BIO Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
15.05.Cabaletta Bio, Inc. - 10-Q, Quarterly Report6
15.05.Cabaletta Bio Announces 2027 Rese-cel BLA Submission Anticipated in Myositis Following Recent FDA Alignment on Registrational Cohorts3
15.05.Cabaletta Bio, Inc. - 8-K, Current Report2
02.04.Patient suffers side effect in Cabaletta autoimmune CAR-T trial, but analysts unfazed7
01.04.UBS cuts Cabaletta Bio stock target to $7, maintains Buy rating3
01.04.Cabaletta Bio Reports Wider Q4 Results As R&D Expenses Rise2
CABALETTA BIO Aktie jetzt für 0€ handeln
01.04.Stifel cuts Cabaletta Bio stock target to $13, maintains buy2
31.03.Cabaletta Bio, Inc. - S-8, Securities to be offered to employees in employee benefit plans-
31.03.Cabaletta Bio, Inc. - 10-K, Annual Report5
31.03.Cabaletta Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update143- FDA meeting to align on myositis registrational trial designs for rese-cel in 1H25 on track - - Enrolling approximately one patient per week across the RESET clinical development program since...
► Artikel lesen
31.03.Cabaletta Bio, Inc. - 8-K, Current Report-
19.02.Cabaletta's CAR-T shows 'robust benefit' in lupus patients, teeing up registrational trial plans6
18.02.Cabaletta Bio, Inc. - 8-K, Current Report1
11.02.Cabaletta Bio Announces Presentations Featuring Updated Clinical Data on Rese-cel at Upcoming Scientific Meetings in February2
13.01.Cabaletta Bio, Inc. - 8-K, Current Report3
08.08.24Cabaletta Bio Reports Second Quarter 2024 Financial Results and Provides Business Update204- Nine patients enrolled as of August 5, 2024 across the RESET clinical development program, including four since EULAR in June, with 22 U.S. clinical sites now enrolling - - Additional clinical data...
► Artikel lesen
14.06.24Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis and RESET-SLE Trials of CABA-201231- No CRS, ICANS, infections or serious adverse events observed in either of the first two patients through data cut-off of May 28, 2024 - - CABA-201 exhibited anticipated profile of CAR T cell expansion...
► Artikel lesen
17 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1